SUMMARY Background
Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking.
Aim
To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission.
Methods
In this cross-sectional cohort study, patients <18 years with Crohn's disease or ulcerative colitis in clinical remission ≥3 months were included. At baseline, clinical and biochemical disease activity were assessed using the abbreviated-Pediatric Crohn's Disease Activity Index or Pediatric Ulcerative Colitis Activity Index, and FC and CRP respectively. Disease course over the subsequent 12 months was retrospectively assessed.
Results
In total, 114 patients (56% males; median age 14.9 years) were included. Baseline FC was higher in patients that developed symptomatic relapse [median (IQR), relapse 370 lg/g (86-1100) vs. remission 122 lg/g (40-344), P = 0.003]. Baseline FC was predictive of symptomatic relapse within 6 months [HR per 250 lg/g (95% CI): 1.46 (1.21-1.77), P < 0.001], with good predictive accuracy (AUC: 0.82). Optimal FC cut-off was 350 lg/g, with positive and negative predictive value of 41% and 96%. Baseline CRP was higher in patients that developed symptomatic relapse [median (IQR), relapse 1.0 lg/g (0. Unfortunately, it is difficult to predict when a relapse will occur.
Biomarkers of inflammation have been suggested to be predictive of symptomatic relapse in patients with IBD. 1 Indeed, studies in adults have shown that level of faecal calprotectin (FC) -arguably the most accurate marker of intestinal inflammation currently available 2 -is predictive of relapse in IBD in clinical remission. 3, 4 Although less accurate, levels of C-reactive protein++ (CRP) have also been reported to be predictive of the risk of relapse. 1, 5, 6 These findings may have important implications for clinical practice, because treating patients in remission guided by biomarkers can potentially increase the likelihood of attaining sustained remission. In support of this, a recent study showed that a therapeutic algorithm based on levels of FC alone can improve long-term outcome in adult patients with ulcerative colitis in clinical remission. 7 In paediatric IBD, the predictive value of biomarkers of inflammation for relapse is not well known. The three studies that have been published to date evaluating this topic reported conflicting results 5, 8, 9 and are hard to interpret because of major methodological flaws, 8 use of non-validated instruments to define remission 5, 8, 9 and the use of nonvalidated instruments 8, 9 or very strict criteria 5 to define relapse.
Therefore, in the present study, we aimed to investigate the predictive value of the biomarkers FC and CRP for the risk of relapse in children and adolescents with IBD in clinical remission.
METHODS

Patients
In this cross-sectional, multi-centre cohort study, we aimed to include all children (aged <18 years) in clinical remission for at least 3 months, with an established diagnosis of Crohn's disease or ulcerative colitis according to the revised Porto criteria. 10 Patients were included at the 
Data collection
Clinical disease activity was evaluated cross-sectionally at baseline by the treating physician using the aPCDAI or PUCAI, for Crohn's disease and ulcerative colitis respectively. A blood sample was taken at baseline to measure serum CRP level and patients were asked to provide a faecal sample at baseline visit for measurement of FC level. The following baseline patient characteristics were extracted from patients' medical records: age, sex, number of months since diagnosis of IBD, current and previous use of IBD related medication, previous IBD related surgery, age at diagnosis, disease location and behavior, and the presence of (previous) growth impairment. The Paris classification was used to classify IBD phenotype.
14 Current medication for IBD was categorised according to a step-up therapeutic pyramid in accordance with the European Crohn's and Colitis Organisation and European Society of Pediatric Gastroenterology, Hepatology and Nutrition guidelines on the medical management of paediatric Crohn's disease or ulcerative colitis: aminosalicylate monotherapy, immunomodulators with or without aminosalicylates, anti-tumour necrosis factor alpha (antiTNFa) with or without aminosalicylates and/or immunomodulators. 15, 16 The following parameters were retrospectively assessed over the 12-month period following baseline (during which patients visited the out-patient paediatric gastroenterology clinic at 3-month intervals) from patients' medical records: clinical disease activity (aPCDAI or PUCAI), change in IBD related medication, all available FC and CRP levels, the occurrence of IBD related surgery and radiological or endoscopic examination. Followup parameters were assessed by a single reviewer (KD), which was not involved in treatment of patients and blinded for baseline FC and CRP. In our practice, cases of suspected symptomatic relapse were confirmed with both FC and CRP levels. Patients and their caretakers were instructed to contact the out-patient paediatric gastroenterology clinic if the child developed symptoms between regular out-patient visits, to arrange an additional out-patient visit to evaluate disease activity.
The primary endpoint was symptomatic relapse defined as an aPCDAI or PUCAI score ≥10, with the need for treatment intensification, defined as either (i) the start of medical treatment (in patients receiving no medical therapy at baseline), (ii) the addition of a new type of medical therapy, and/or (iii) dose escalation of maintenance treatment.
Statistical analysis
Primary analysis was the independent predictive value of FC for symptomatic relapse. Secondary analysis was the independent predictive value of CRP for symptomatic relapse. Continuous data with a normal distribution were presented as mean and standard deviation (s.d.), and paired or unpaired t-tests were used to compare differences between groups. Continuous data with a non-normal distribution were presented as median and interquartile range (IQR), and Mann-Whitney U tests or Wilcoxon signed rank test were used to compare differences between groups. Categorical data were presented as percentages. Time-to-event data were presented using Kaplan-Meier curves for all IBD patients, and separately for Crohn's disease and ulcerative colitis patients.
Univariable and multivariable Cox regression analysis was performed to evaluate whether FC and CRP could serve as independent predictors for symptomatic relapse. We hypothesised that the predictive accuracy of FC and CRP for symptomatic relapse gradually decreases over time. Therefore, stratum specific survival plots and logminus-log plots were analysed to evaluate a potential time-varying effect. 17 When a time-varying effect of FC or CRP was present, a cut-off time-point was established up until the hazard for symptomatic relapse was proportional, which was then verified in a Cox model by testing difference in hazard between the period before and after the established cut-off time-point, as described previously. 17 When no clear time-varying effect was present, a 6-month cut-off time-point was tested as described above. Proportional hazard assumptions of other predictive factors were graphically evaluated using log-minuslog plots. The predictive value of FC and CRP was adjusted in multivariable Cox regression for all variables with a two-sided P < 0.20 in univariable Cox regression. Hazard ratios (HR) were presented per 100 lg/g increment for FC levels and per 1 mg/L increment for CRP levels. A cut-off for FC and CRP levels with the highest sum of sensitivity and specificity was determined using receiver operating characteristic (ROC) analysis. Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios with 95% CIs for the prediction of a symptomatic relapse were calculated for (i) the identified cut-offs, (ii) for established cut-offs for endoscopic activity (FC 250 lg/g 2 ; CRP 5 mg/L 18 ) and (iii) for cut-offs with the highest sensitivity at a specificity level ≥90%. The accuracy of FC and CRP was evaluated using the area under the curve (AUC) of the ROC and was classified as follows: poor 0.6-0.7; fair 0.7-0.8; good 0.8-0.9; excellent 0.9-1.0. 19 The level of significance was set at P < 0.05. Statistical analysis was performed using IBM SPSS Statistics 22 (Chicago, IL, USA) for Windows.
RESULTS
Patient characteristics
One hundred twenty patients were in clinical remission for at least 3 months based on activity indices, of whom six patients were excluded due to diarrhoea (n = 2), unintentional weight loss (n = 1), fever (n = 1) or active perianal disease (n = 2). In total, 114 patients (56% male), with a mean age of age was 14.9 years (IQR: 12.6-16.5), were included: 70 with Crohn's disease and 44 with ulcerative colitis. Median duration of disease was 27.6 months (IQR: 13.6-55.7). None of the patients smoked. Eighty-six patients (75%) reported no IBDrelated symptoms, 27 patients (24%) reported mild abdominal pain and one patient (1%) reported occasional limitation of activity. Maintenance treatment was not adjusted in the majority of patients (90.4%) within 3 months prior to inclusion: in three patients (2.6%) the dose was adjusted according to weight; in four patients (3.5%) treatment was stopped or the dose was reduced due to sustained remission; in four patients (3.5%) the dose or type was adjusted due to adverse events. The cumulative number of patients with symptomatic relapse was nine (8%), 17 (15%) and 27 (24%) patients at 3, 6 and 12 months after baseline respectively. In the patients that went on to symptomatic relapse, 21 (78%) received an additional type of medical therapy, 4 (15%) received dose escalation of maintenance treatment, and two (7%) re-started medical treatment. Baseline characteristics of patients with and without symptomatic relapse are shown in Table 1 .
Risk of symptomatic relapse
In multivariable Cox regression analysis, FC, CRP and the type of IBD [UC vs. CD, HR: 2.65 (95% CI: 1.14-6.32), P = 0.028] were significantly associated with the risk of symptomatic relapse (Table 2) .
Faecal calprotectin. Baseline faecal calprotectin (FC) levels were higher in patients that developed a relapse compared to patients with no symptomatic relapse [median 370 lg/g (IQR 86-1100) vs. 112 lg/g (IQR 40-344), P = 0.003]. In patients with symptomatic relapse A1a: 0-<10 years (n, %) 3 (27%) 18 (31%) A1b: 10-<17 years (n, %) (Paris classification) B1: nonstricturing, nonpenetrating (n, %) 9 (82%) 51 (86%) B2: structuring (n, %) 2 (18%) 1 (2%) B3: penetrating (n, %) 0 (0%) 7 (12%) B2B3: penetrating and stricturing (n, %) 0 (0%) 0 (0%) p: perianal disease (n, %) 2 (18%) 11 (19%) Crohn's disease: growth impairment (Paris classification)
Evidence of growth delay (n, %) 0 (0%) 14 (24%) Ulcerative colitis: extent (Paris classification) E1: proctitis (n, %) 4 (15%) 2 (7%) E2: left-sided disease (n, %) 3 (19%) 7 (25%) E3: extensive disease (n, %) 0 (0%) 3 (11%) E4: pancolitis (n, %) 9 (56%) 16 (57%) Ulcerative colitis: severity (Paris classification) S1: ever severe (n, %) 3 (11%) 4 (5%)
anti-TNFa, anti-tumour necrosis factor alpha; IBD, inflammatory bowel disease; NA, not applicable. Multivariable analysis demonstrated that FC level was an independent predictor of symptomatic relapse within 6 months from baseline (HR: 1.46 [95% CI: 1.21-1.77], P < 0.001; Table 2 ). In a separate analysis of Crohn's disease and ulcerative colitis, FC level was independently predictive of symptomatic relapse for both diagnoses [Crohn's disease: HR: 1.51 (95% CI: 1.11-2.07), P = 0.010; ulcerative colitis: HR: 1.47 (95% CI: 1.12-1.92), P = 0.005; Table S1 ].
Baseline FC level had a good accuracy for predicting symptomatic relapse until 6 months from baseline [AUC: 0.82 (95% CI: 0.71-0.93), P < 0.001, Figure 2 ]. The cut-off level for FC with the highest combined sensitivity and specificity was 350 lg/g. If FC level was > 350 lg/g, the chance of symptomatic relapse was 41%, and if FC level was <350 lg/g the chance of sustained remission was 96%, within 6 months from baseline. The FC level with the highest sensitivity at a specificity ≥90% was 850 lg/g. Test characteristics of FC cut-off levels are shown in Table 3 . Time to symptomatic relapse survival curves of patients with CRP levels below 5 mg/L compared to patients with CRP levels above 5 mg/L exhibited a proportional hazard of symptomatic relapse within 12 months from baseline (Figure 1b) . However, when analysed per semester in univariable analysis, CRP level was a significant predictor of relapse within 6 months Multivariable analysis demonstrated that CRP level was an independent predictor of symptomatic relapse within 6 months from baseline [HR: 1.10 (95% CI:
1.02-1.19), P = 0.011; Table 2 ]. In a separate analysis of Crohn's disease and ulcerative colitis, CRP level was independently predictive of symptomatic relapse for both diagnoses [Crohn's disease: HR: 1.14 (95% CI: 1.03-1.26), P = 0.009; ulcerative colitis: HR: 1.17 (95% CI: 1.00-1.37), P = 0.046; Table S1 ].
Baseline CRP level had a fair accuracy for predicting symptomatic relapse within 6 months from baseline [AUC: 0.72 (95% CI: 0.58-0.85), P = 0.006, Figure 2 ]. The cut-off for CRP with the highest combined sensitivity and specificity was 1.0 mg/L. If CRP level was >1.0 mg/L, the chance of symptomatic relapse was 21%, and if CRP level was <1.0 mg/L the chance of sustained remission was 94%, within 6 months from baseline. The CRP level with the highest sensitivity at a specificity ≥90% was 5.0 mg/L. Test characteristics of CRP cut-off levels are shown in Table 3 .
DISCUSSION
In this study, we demonstrated that levels of FC and CRP were both independent predictors of symptomatic relapse in children and adolescents with IBD in clinical remission, and in Crohn's disease and ulcerative colitis separately. Faecal calprotectin was a more accurate predictor compared to CRP. Furthermore, the risk of symptomatic relapse was higher in patients with ulcerative colitis compared to patients with Crohn's disease. Faecal calprotectin level has already been shown to be predictive of symptomatic relapse in adult patients with IBD. 3, 4, 20 Similar to our results, the majority of studies in adults found a higher FC level in patients who developed a relapse compared with those who remained in clinical remission. 21, 22 Reported cut-off of FC to identify adults with IBD with a higher risk of relapse varied greatly, ranging from 120 to 340 lg/g. 4 The two published paediatric IBD studies reported cut-off values for FC of 108 9 and 500 lg/g. 5 The cut-off for the FC level with the highest combined sensitivity and specificity in this study (350 lg/g) is higher than most previously reported cut-offs in adults. This may be related to a shorter duration of follow-up of 6 months, used for prediction of symptomatic relapse in the present study, compared to 12 months in most studies on adult patients. 1, 21, 22 Indeed, levels of FC are shown to be less increased as relapse occurs later in time. 23, 24 Furthermore, the use of only clinical indices for the definition of relapse 25, 26 or strictly defined patient populations (e.g.
patients on anti-TNFa) may have resulted in lower FC cut-off levels in previous studies on adults. 26 The difference between our identified optimal FC cut-off level and previous paediatric cohorts may be related to differences in the definition of clinical remission and the duration of follow-up. 5, 9 Moreover, the reported previous studies used nonvalidated instruments 9 or very strict criteria 5 to define relapse. Test characteristics of FC level in predicting symptomatic relapse showed fair predictive accuracy (AUC 0.82) and reasonable sensitivity (82%) and specificity (79%) for the optimal cut-off level. A meta-analysis on the predictive value of FC for symptomatic relapse of six prospective studies in adults showed similar pooled area under the curve (0.83), sensitivity [78% (95% CI: 72-83)] and specificity [73% (95% CI: 68-77)]. 3 The predictive value of CRP for symptomatic relapse in patients with IBD in clinical remission is less well established. While some studies in adult patients found higher CRP levels in those that went on to relapse, 27, 28 most study groups did not find such a difference. 1, 6, 25, 29, 30 In addition, levels of CRP did not significantly differentiate between patients with and without symptomatic relapse by ROC analysis and had no value in predicting relapse in previous paediatric 5 and adult studies. 1, 6 Although CRP was an independent predictor of symptomatic relapse in the present study, the predictive accuracy (AUC: CRP 0.72 vs. FC 0.82) and test characteristics at the optimal cut-off level (PPV: CRP 21% vs. FC 41%) was inferior to FC. The rationale for less accurate prediction of relapse using CRP may be related to its lower specificity for IBD activity compared to the more gut specific inflammatory marker such as FC. [31] [32] [33] Furthermore, a known genetic CRP polymorphism in the general population which is associated with variations in CRP concentrations, with prevalence's reported up to 20%, 34 could also contribute to lower predictive accuracy of CRP for symptomatic relapse in our cohort and previous studies. 1, 5, 6 In this study, we only used cases of relapse within 6 months from baseline to predict symptomatic relapse, as both FC and CRP levels were not predictive from 6 to 12 months from assessment. This confined period during which FC and CRP are predictive of symptomatic relapse corresponds to previous studies on patients with IBD in clinical remission, in whom serial measurement of FC and CRP were performed after discontinuation of infliximab. 23, 24 Faecal calprotectin and CRP levels only started to increase 3-6 months before clinical relapse. Crohn's disease and ulcerative colitis are diseases with distinct inflammatory characteristics. Consequently, the predictive value of FC and CRP for relapse may be different for these two diseases. This study, however, demonstrated similar predictive capacity of FC in Crohn's disease and ulcerative colitis. This is in accordance with a meta-analysis including prospective studies in adults patients, which did not identify a difference in the predictive value of FC for relapse in Crohn's disease and ulcerative colitis.
3 C-reactive protein levels were also similarly predictive in Crohn's disease and ulcerative colitis in our study, which seems counterintuitive, considering that the accuracy of CRP for the identification of endoscopically active ulcerative colitis is poor. 35, 36 An important aspect in the use of a single measurement of FC to predict relapse, as evaluated in the present study, is the variability in the level of FC during periods of clinical remission. Although FC level in IBD patients with active disease shows great variability within and between days, 37 reassuringly, a study in Crohn's disease patients in clinical remission showed that day to day variability in FC levels was low [ICC 0.84 (95% CI: 0.79-0.89)]. 38 Another concern in using FC for the prediction of symptomatic relapse, especially in Crohn's disease, is differential accuracy dependent on disease location (e.g. colonic vs. isolated small bowel disease). To date, findings of studies have not been univocal. A cross-sectional study on Crohn's disease patients evaluating the accuracy of FC for macroscopic inflammation, as determined by complete colonic and small bowel endoscopy, reported that FC is equally accurate in colonic disease compared to isolated small bowel disease, 39 while a more recent study with similar methodology reported lower levels of FC in patients with isolated small bowel disease. 40 In the present study, a direct comparison between Crohn's disease patients with and without colonic involvement was not feasible due to the low number of patients with isolated small bowel disease. Therefore, the predictive value of FC level for relapse in patients with isolated small bowel Crohn's disease remains elusive. Surprisingly, paediatric patients with ulcerative colitis in our cohort had a twofold higher risk of symptomatic relapse during follow-up compared to those with Crohn's disease. In contrast, previous studies in adults with IBD did not find such an association. 1, 9, 29 The association in this study may be related to the higher rate of antiTNFa agent use, hence a greater potency of suppressing inflammation, in patients with Crohn's disease compared to ulcerative colitis (Crohn's disease 40% vs. ulcerative colitis 7%, P < 0.001). We however did not find an association between use of anti-TNFa agents and the risk of symptomatic relapse, nor did the lone previous study which also reported the effect of anti-TNFa on symptomatic relapse in adults with IBD in clinical remission. 20 Nevertheless, the number of anti-TNFa users that subsequently relapsed, in our cohort and the latter study, were low, which may have impeded determination of an accurate association. Strength of our study is that we included paediatric patients with IBD in clinical remission for at least 3 months using a strict definition, thereby reducing the potential influence of preceding flares on baseline level of biochemical markers of inflammation. A limitation of our study is the retrospective nature and, consequently, the nonsystematic follow-up of patients. However, all patients attended the out-patient clinic at regular intervals after baseline assessment and extraction of clinical disease activity from medical records was feasible at every out-patient visit using the aPCDAI and PUCAI. Furthermore, due to ethical considerations, the treating physicians were aware of the results of baseline biochemical marker measurement, which might have influenced the clinical management during follow-up. Moreover, we used clinical activity indices to define remission at baseline, rather than endoscopy, while the latter may be considered the gold standard to assess IBD activity. 41 Although clinical disease activity is known to correlate poorly with more objective measurement of disease activity, 42, 43 we evaluated the predictive value of biochemical markers of inflammation for symptomatic relapse due to its negative impact on patients' quality of life. 44 Indeed, although endoscopy-guided management of IBD is increasingly recommended, 45 its true value remains to be evaluated prospectively. Many children with IBD in clinical remission have elevated biomarkers of inflammation. 42 As there is currently no clear guidance, the management of these patients may pose dilemmas for the treating physician. Should these patients undergo endoscopy -with its associated risk, costs and discomfort -to ascertain the presence of endoscopic inflammation, while its shortand long-term relevance remains to be elucidated? Or should treatment be intensified -with a potential risk of overtreatment of patients with a benign disease course, thereby subjecting certain patients to an unnecessary risk of side-effects? Based on our results, intensifying medical treatment cannot be recommended in all children with elevated biomarkers of inflammation. Indeed, despite the observed predictive value of FC for relapse, the majority of patients in our study with baseline FC levels of >250 lg/g was still in clinical remission after 12 months. A higher cut-off for FC (resulting in an increased specificity) may potentially be used to reliably identify candidates for treatment intensification. In our study, 56% of patients with a baseline FC level >850 lg/g went on to relapse within 6 months. We hypothesise that patients in clinical remission with highly elevated FC levels are likely to benefit from treatment intensification. Nonetheless, before such a strategy can be adopted in routine care, our findings should be replicated in an independent cohort, and ideally, it should be evaluated prospectively whether treatment of paediatric IBD guided by FC levels reduces the risk of relapse and improves quality of life.
In conclusion, in this study on children and adolescents with IBD in clinical remission, FC and CRP level were both found to be independent predictors of symptomatic relapse, with superior predictive test characteristics of FC. These results suggest that high FC levels found at routine measurement in children and adolescents with IBD in clinical remission justify more careful disease monitoring and should prompt critical evaluation of current treatment.
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